Newsletter Tool

Today's Rundown

Amazon expanding healthcare service to 20 more cities, lands Silicon Labs, Whole Foods Market as customers
Pfizer tidies up pipeline while eyeing external science to add $25B in revenue by 2030
Amgen talks long-term growth, but doubts remain for analysts, investors
CooperSurgical to acquire Cook Medical's IVF, OB-GYN businesses for $875M
Eli Lilly, Innovent's PD-1 in troubled waters as FDA review, oncology chief's comments portend likely rejection
Anthem rolling out virtual primary care to plans in 11 states
Axsome’s migraine drug finally slated for FDA inspection, but investors want to know about stalled depression therapy
GN’s Jabra sends self-fitting hearing aids to market for $799 ahead of FDA over-the-counter ruling
J&J pauses COVID-19 vaccine production at Dutch plant in temporary pivot to RSV shot: NYT
CVS teams with Medable to expand access to clinical trials
Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X
Second Sight eyes buyout of Nano Precision Medical and its diabetes drug implant

Featured Story

Amazon expanding healthcare service to 20 more cities, lands Silicon Labs, Whole Foods Market as customers

By Heather Landi

Amazon has signed on three more companies for its virtual and in-person healthcare services as it continues to target the employer market.

Pfizer tidies up pipeline while eyeing external science to add $25B in revenue by 2030

By Kyle LaHucik

Pfizer is doing a little house cleaning of its pipeline, but not to worry. CEO Albert Bourla is expecting to bring on external science that could help reap "at least $25 billion of risk-adjusted revenues" by 2030.

Amgen talks long-term growth, but doubts remain for analysts, investors

By Kevin Dunleavy

Amgen is projecting compound annual growth in mid-single digits through the end of this decade. Considering the company reported 2021 revenue at $26.0 billion, that level of growth would get Amgen to roughly $35 billion in revenue in 2030, which is an ambitious goal according to analysts and investors.

CooperSurgical to acquire Cook Medical's IVF, OB-GYN businesses for $875M

By Conor Hale

Cook’s subsidiaries will continue to manufacture products for CooperSurgical during a two-year transition.

Eli Lilly, Innovent's PD-1 in troubled waters as FDA review, oncology chief's comments portend likely rejection

By Angus Liu

An FDA rebuff looks almost certain for Eli Lilly and partner Innovent Biologics’ PD-1 inhibitor Tyvyt as an overwhelmingly negative internal FDA review ahead of an advisory committee meeting suggests the agency is unwilling to consider a drug solely based on clinical data from China.

Anthem rolling out virtual primary care to plans in 11 states

By Paige Minemyer

Anthem will make virtual primary care available to eligible members of its commercial health plans in 11 states, the insurer announced Tuesday.

Axsome’s migraine drug finally slated for FDA inspection, but investors want to know about stalled depression therapy

By Max Bayer

The FDA will in fact be able to inspect Axsome’s manufacturing facility for its migraine drug by the decision date as the agency gets these crucial inspections back on track following COVID disruptions.

GN’s Jabra sends self-fitting hearing aids to market for $799 ahead of FDA over-the-counter ruling

By Andrea Park

The Enhance Plus earbuds have been cleared by the FDA as self-fitting hearing aids.

J&J pauses COVID-19 vaccine production at Dutch plant in temporary pivot to RSV shot: NYT

By Fraiser Kansteiner

The news that Johnson & Johnson stopped making its pandemic vaccine at a key European plant came as a bit of a shock. Not to worry, though, the company says—the production pause was all part of the plan and should be over by next month.

CVS teams with Medable to expand access to clinical trials

By Paige Minemyer

CVS Health is teaming up with Medable to access and engage around clinical trials at select MinuteClinics, the healthcare giant announced Monday.

Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X

By Nick Paul Taylor

Ovid Therapeutics has found a potential buyer for its onetime lead program. A little more than one year after gaboxadol’s value-crushing phase 3 flop, Healx has stepped in to see whether it can write another chapter in the long, failure-strewn history of the neurological disease drug.

Second Sight eyes buyout of Nano Precision Medical and its diabetes drug implant